Adjuvant chemotherapy for primary cardiac sarcomas: the IGR experience
1998

Chemotherapy for Primary Cardiac Sarcomas

Sample size: 15 publication Evidence: low

Author Information

Author(s): A Liombart-Cussac, X Pivot, G Contesso, A Rhor-Alvarado, JP Delord, M Spielmann, T TOrsz, A Le Cesne

Primary Institution: Institut Gustave Roussy

Hypothesis

The study aims to evaluate the benefit of chemotherapy in patients with non-metastatic cardiac sarcomas after optimal resection.

Conclusion

Post-operative conventional doxorubicin-based chemotherapy failed to modify the natural history of patients with resected cardiac sarcomas.

Supporting Evidence

  • 13 out of 15 patients relapsed after treatment.
  • Median overall survival was 12 months.
  • 2-year survival rate was 26%.
  • Patients with completely resected tumors had longer survival than those with incomplete resections.

Takeaway

This study looked at patients with rare heart tumors and found that chemotherapy after surgery didn't help them live longer.

Methodology

The study analyzed 15 patients who underwent resection of primary cardiac sarcoma and received adjuvant chemotherapy.

Potential Biases

Potential selection bias due to the retrospective nature and exclusion of patients with unresectable tumors.

Limitations

The study is retrospective and has a small sample size.

Participant Demographics

Median age of participants was 45 years, with 11 males and 4 females.

Statistical Information

P-Value

P < 0.01

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication